Literature DB >> 33849545

High CFP score indicates poor prognosis and chemoradiotherapy response in LARC patients.

Siyi Lu1, Zhenzhen Liu1, Bingyan Wang1, Fei Li1, Yan Meng1, Junwei Wang1, Yuxia Wang2, Hao Wang3, Xin Zhou4, Wei Fu5.   

Abstract

BACKGROUND: Preoperative tumor markers, inflammation, and nutritional status are considered important predictors of prognosis and tumor response in locally advanced rectal cancer (LARC) patients. This study aims to explore the prognostic and predictive role of carcinoembryonic antigen (CEA), the Fibrinogen-Albumin Ratio Index (FARI), the Prognostic Nutritional Index (PNI) in LARC patients and compared them with a novel combined CEA-FARI-PNI (CFP) scoring system.
METHODS: A total of 138 LARC patients undergoing radical surgery following neoadjuvant chemoradiotherapy (NCRT) between January 2012 and March 2019 were enrolled. The X-tile program was used to determine the optimal cut-off values of CEA, FARI, and PNI, and CFP scoring system was constructed accordingly. The prognostic ability of these factors was assessed by the time-dependent receiver operating characteristic (ROC) curve, Kaplan-Meier, Cox regression, and logistic regression. Nomogram was established to evaluate the predictive role of these factors in tumor response.
RESULTS: The optimal cut-off values of CEA, FARI, and PNI were 5.15 ng/l, 10.56%, and 42.25 g/L, respectively. The time-dependent ROC curve showed that compared to CEA, FARI, and PNI, CFP showed stable predictive efficacy for overall survival (OS) and disease-free survival (DFS). In multivariate analysis, CFP was the only factor that could independently predict OS (HR = 8.117, p = 0.001) and DFS (HR = 4.994, p < 0.001). Moreover, high CFP (OR = 3.693, p = 0.002) was also an independent risk factor of poor response. The area under the ROC curve (AUC) of the nomograms for predicting tumor response was better including CFP (0.717) than without CFP (0.656) (p < 0.05).
CONCLUSIONS: The CFP score was a more reliable marker for predicting OS, DFS, and NCRT efficacy in LARC patients, and the score could apparently improve predicted efficacy of the nomogram.

Entities:  

Keywords:  CFP; Prognosis; Rectal cancer; Tumor regression grade

Year:  2021        PMID: 33849545     DOI: 10.1186/s12935-021-01903-1

Source DB:  PubMed          Journal:  Cancer Cell Int        ISSN: 1475-2867            Impact factor:   5.722


  36 in total

1.  Colorectal cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ann Goding Sauer; Stacey A Fedewa; Lynn F Butterly; Joseph C Anderson; Andrea Cercek; Robert A Smith; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-03-05       Impact factor: 508.702

2.  The role of carcinoembryonic antigen after neoadjuvant chemoradiotherapy in patients with rectal cancer.

Authors:  Na Young Jang; Sung-Bum Kang; Duck-Woo Kim; Jee Hyun Kim; Keun-Wook Lee; In Ah Kim; Jae-Sung Kim
Journal:  Dis Colon Rectum       Date:  2011-02       Impact factor: 4.585

3.  Adjuvant Chemotherapy Does Not Improve Recurrence-Free Survival in Patients With Stage 2 or Stage 3 Rectal Cancer After Neoadjuvant Chemoradiotherapy and Total Mesorectal Excision.

Authors:  Rachel K Voss; Jane C Lin; Michelle T Roper; Mohammed H Al-Temimi; Joseph H Ruan; Warren H Tseng; Michael Tam; Matthew J Sherman; Daniel D Klaristenfeld; Marco J Tomassi
Journal:  Dis Colon Rectum       Date:  2020-04       Impact factor: 4.585

Review 4.  Cancer-related inflammation.

Authors:  Juliana Candido; Thorsten Hagemann
Journal:  J Clin Immunol       Date:  2012-12-09       Impact factor: 8.317

Review 5.  Colorectal cancer.

Authors:  Ernst J Kuipers; William M Grady; David Lieberman; Thomas Seufferlein; Joseph J Sung; Petra G Boelens; Cornelis J H van de Velde; Toshiaki Watanabe
Journal:  Nat Rev Dis Primers       Date:  2015-11-05       Impact factor: 52.329

6.  Disease-free Survival and Local Recurrence for Laparoscopic Resection Compared With Open Resection of Stage II to III Rectal Cancer: Follow-up Results of the ACOSOG Z6051 Randomized Controlled Trial.

Authors:  James Fleshman; Megan E Branda; Daniel J Sargent; Anne Marie Boller; Virgilio V George; Maher A Abbas; Walter R Peters; Dipen C Maun; George J Chang; Alan Herline; Alessandro Fichera; Matthew G Mutch; Steven D Wexner; Mark H Whiteford; John Marks; Elisa Birnbaum; David A Margolin; David W Larson; Peter W Marcello; Mitchell C Posner; Thomas E Read; John R T Monson; Sherry M Wren; Peter W T Pisters; Heidi Nelson
Journal:  Ann Surg       Date:  2019-04       Impact factor: 12.969

7.  Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group.

Authors:  Laurence Collette; Jean-Francois Bosset; Marcel den Dulk; France Nguyen; Laurent Mineur; Philippe Maingon; Ljiljana Radosevic-Jelic; Marianne Piérart; Gilles Calais
Journal:  J Clin Oncol       Date:  2007-10-01       Impact factor: 44.544

8.  The role of carcinoembriogenic antigen in predicting response and survival to neoadjuvant chemoradiotherapy for distal rectal cancer.

Authors:  Rodrigo O Perez; Guilherme P São Julião; Angelita Habr-Gama; Desidério Kiss; Igor Proscurshim; Fabio Guilherme Campos; Joaquim J Gama-Rodrigues; Ivan Cecconello
Journal:  Dis Colon Rectum       Date:  2009-06       Impact factor: 4.585

9.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

10.  Prognostic impact of preoperatively elevated and postoperatively normalized carcinoembryonic antigen levels following curative resection of stage I-III rectal cancer.

Authors:  Yuya Nakamura; Dai Shida; Taro Tanabe; Yasuyuki Takamizawa; Jun Imaizumi; Yuka Ahiko; Ryohei Sakamoto; Konosuke Moritani; Shunsuke Tsukamoto; Yukihide Kanemitsu
Journal:  Cancer Med       Date:  2019-12-04       Impact factor: 4.452

View more
  2 in total

Review 1.  Biomarkers of Favorable vs. Unfavorable Responses in Locally Advanced Rectal Cancer Patients Receiving Neoadjuvant Concurrent Chemoradiotherapy.

Authors:  Hsin-Hua Lee; Chien-Hung Chen; Yu-Hsiang Huang; Cheng-Han Chiang; Ming-Yii Huang
Journal:  Cells       Date:  2022-05-11       Impact factor: 7.666

2.  Impact of Body Composition During Neoadjuvant Chemoradiotherapy on Complications, Survival and Tumor Response in Patients With Locally Advanced Rectal Cancer.

Authors:  Zhenzhen Liu; Siyi Lu; Yuxia Wang; Xinyi Lin; Peng Ran; Xin Zhou; Wei Fu; Hao Wang
Journal:  Front Nutr       Date:  2022-01-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.